Rajeev K. Tyagi

CSIR-Institute of Microbial Technology, Chandigarh

Dr. Tyagi has been leading a group at CSIR-Institute of Microbial Technology, Chandigarh, India. He obtained his Ph.D. in 2011 at the Biomedical Parasitology Unit, Institute Pasteur, Paris, where he developed a long-lasting, stable and straightforward laboratory animal model (humanized mouse model). Dr. Tyagi’s post-doctoral work was carried out at the University of South Florida, Augusta University and Vanderbilt University Medical Center (VUMC), USA, where he used the humanized mouse model as a tool to study the infectious disease P. falciparum and inflammatory diseases (P. gingivalis, colitis). His current research group is working on the development of human-liver chimeric mice for huHep transplantation, the antimalarial and anti-inflammatory potential of oleuropein has been explored in the asexual blood stage infection of P. falciparum and in-vitro models of inflammation (LPS- stimulated human THP-1 macrophages), and. on formulation and characterization of nanoscale drug carriers to deliver methotrexate (MTX) and aceclofenac in the treatment of rheumatoid arthritis, breast cancer and other inflammatory diseases.

Rajeev K. Tyagi

3books edited

2chapters authored

Latest work with IntechOpen by Rajeev K. Tyagi

The role of nanoscale drug carriers for the effective and controlled delivery of drugs and candidate antigens is instrumental in developing therapeutic and vaccine interventions for cancers, infectious diseases and beyond. As teachers of immunobiology, we think this information will contribute to the development of interventional approaches. This book, therefore, will be a valuable addition to existing knowledge in many medical schools and undergraduate courses, providing up-to-date information on drugs and their delivery for maximum therapeutic effect and vaccination potential against infectious diseases, cancers and more. Novel drugs are described, with an assessment of their effective delivery and of drug resistance, especially against cancers. The book is a timely addition to the existing literature on lipid-based nanoparticles and will be a useful resource for students, researchers, and those working in the field of drugs, drug delivery, and drug resistance in infectious and inflammatory diseases.

Go to the book